Investors

DCprime Merger Information

On Wednesday, November 18th Immunicum and DCprime combined forces to establish the company as a leader in cell-based cancer immunotherapies. To view the full announcement, please click here.

About DCprime
DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. Our lead product is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse. We are pursuing similar vaccination approaches for solid tumors. We believe relapse vaccines will improve survival by putting the patient’s immune system back in control.

 

Immunicum Virtual Investor Event – 9 December 2020 at 15.00 CET

To view the webcast, click here.

To view the Investor Event presentation, click here.

To view the Investor Event press release, click here.

To view the Frequently Asked Questions, click here.

Extraordinary General Meeting – 18 December 2020

For the information and documentation of the EGM (including forms for postal voting and power of attorney), please click here.

Granted Exemption to VHI

Aktiemarknadsnämndens uttalande 2020

Prospectus

To download the prospectus, please click here.

Relevant Links:

Immunicum’s Announcement Presentation:
To view a replay of the webcast, please click here.
To view the presentation, please click here.

 

Recent DCprime publications & presentations prior to the announcement:

ASH 2020 – Virtual
Interim Clinical Data of ADVANCE II Trial. To download the poster, please click here.

SITC 2020 – Virtual
Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer: To download the poster, please click here.

EHA 2020 – Virtual
Development of a humanised immunocompetent mouse model to study the relapse vaccine DCP-001. To download the poster, please click here.

ASH 2019
Durable responses and survival in high-risk AML and MDS patients treated with an allogeneic leukemia-derived dendritic cell vaccine. To download the poster, please click here.

SITC 2019
Novel vaccination strategies using tumour-independent antigens to induce anti-tumour immunity in solid tumours. To download the poster, please click here.

Secured Rights Issue 2017 & 2018

Important information

The information contained in this section of Mendus AB (publ)’s (the “Company”) website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, except as stated below, to persons resident or physically present in the United States of America (including its territories and provinces, any state of the United States and the District of Columbia) (the “United States”), Canada, Japan, Australia, Hong Kong, New Zeeland, Singapore or South Africa or any jurisdiction where participation would require an additional prospectus, registration or measures other than those required by Swedish law. No measures have been or will be taken in any jurisdiction other than Sweden that would permit the shares to be offered to the public or admitted to trading, or permit this Prospectus or any other documents pertaining to the Company or the shares in the Company to be held or distributed in such a jurisdiction. Accordingly, the Prospectus and other documents pertaining to the Offer may not be distributed in or to the aforementioned countries or to any other jurisdiction where distribution or the Offer requires such action or is otherwise in violation of the applicable regulations.

The information contained in this section of Mendus AB (publ)’s (the “Company”) website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, except as stated below, to persons resident or physically present in the United States of America (including its territories and provinces, any state of the United States and the District of Columbia) (the “United States”), Canada, Japan, Australia, Hong Kong, New Zeeland, Singapore or South Africa or any jurisdiction where participation would require an additional prospectus, registration or measures other than those required by Swedish law. No measures have been or will be taken in any jurisdiction other than Sweden that would permit the shares to be offered to the public or admitted to trading, or permit this Prospectus or any other documents pertaining to the Company or the shares in the Company to be held or distributed in such a jurisdiction. Accordingly, the Prospectus and other documents pertaining to the Offer may not be distributed in or to the aforementioned countries or to any other jurisdiction where distribution or the Offer requires such action or is otherwise in violation of the applicable regulations.

The Securities have neither been approved nor rejected by the U.S. Securities and Exchange Commission (“SEC”), any state securities authority or other authority in the United States. Moreover, no such authority has evaluated or expressed an opinion on the accuracy or reliability of the information available on this website. To assert the contrary is a criminal offense in the United States.

Access to the information and documents contained on the following website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons residing outside of Sweden who wish to have access to the documents contained on this website should firstly ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval of any acquisition of Securities by them. No such registration or approval has been obtained outside Sweden. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.

For accessing secured rights issue 2017

I therefore certify that:

1. I am resident and physically present outside the United States, Canada, Japan, Australia, Hong Kong, New Zeeland, Singapore or South Africa.
2. I am resident and physically present (a) in Sweden or (b) outside Sweden and each of the jurisdictions referred to in clause (1) above and, in that case, I am authorized to access the information and documents on this website without being subject to any legal restriction and without any further action required by the Company.
3. I have read, understand and agree to comply with all of the restrictions set forth above.

For accessing secured rights issue 2018

1. I am resident and physically present outside the United States, Canada, Japan, Australia, Hong Kong, New Zeeland, Singapore or South Africa.
2. I am resident and physically present (a) in Sweden or (b) outside Sweden and each of the jurisdictions referred to in clause (1) above and, in that case, I am authorized to access the information and documents on this website without being subject to any legal restriction and without any further action required by the Company.
3. I have read, understand and agree to comply with all of the restrictions set forth above.